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Lymph-borne CD8aþ dendritic cells are uniquely
able to cross-prime CD8þ T cells with antigen
acquired from intestinal epithelial cells
V Cerovic1, SA Houston1, J Westlund2, L Utriainen1, ES Davison1, CL Scott1, CC Bain1, T Joeris3,
WW Agace3,4, RA Kroczek5, AM Mowat1, U Yrlid2 and SWF Milling1
Cross-presentation of cellular antigens is crucial for priming CD8þ T cells, and generating immunity to intracellular
pathogens—particularly viruses. It is unclear which intestinal phagocytes perform this function in vivo. To address this,
weexamineddendritic cells (DCs) fromthe intestinal lymphof IFABP-tOVA232-4mice,whichexpressovalbumin in small
intestinal epithelial cells (IECs). Among lymph DCs (LDCs) only CD103þ CD11b CD8aþ DCs cross-present
IEC-derived ovalbumin to CD8þ OT-I T cells. Similarly, in the mesenteric lymph nodes (MLNs), cross-presentation of
IEC–ovalbumin was limited to the CD11cþ MHCIIhi CD8aþ migratory DCs, but absent from all other subsets, including
the resident CD8ahi DCs. Crucially, delivery of purified CD8aþ LDCs, but not other LDC subsets, into the MLN
subcapsular lymphatic sinus inducedproliferationof ovalbumin-specific, gut-tropicCD8þ Tcells in vivo. Finally, in 232-4
mice treated with R848, CD8aþ LDCs were uniquely able to cross-prime interferon c-producing CD8þ Tcells and drive
their migration to the intestine. Our results clearly demonstrate that migrating CD8aþ intestinal DCs are indispensable
for cross-presentation of cellular antigens and, in conditions of inflammation, for the initial differentiation of effector
CD8þ T cells. They may therefore represent an important target for the development of antiviral vaccinations.
INTRODUCTION
Cross-presentation is the process by which exogenous antigens
are displayed on major histocompatibility complex (MHC)
class I molecules to CD8þ T cells and is necessary for the
generation of cytotoxic T-cell (CTL) responses against tumors
and intracellular pathogens, such as viruses. It has long been
recognized that the capacity to cross-present is limited to a
relatively small population of dendritic cells (DCs). In murine
lymphoid tissues these cells are characterized by expression of
CD8a.1 Cross-presenting lymphoid tissue CD8aþ DCs also
have a high capacity for uptake of apoptotic cells,2 and, in
conditions of inflammation, initiate the differentiation of naive
CD8þ T cells into CTLs in a process known as cross-
priming.3,4 Cross-presentation by non-lymphoid ‘‘peripheral’’
tissue DCs is less well understood. It was suggested that
peripheral DCs are unable to directly cross-present antigen
aftermigrating to the draining lymph nodes (LNs),5 andmerely
serve to transfer peripheral antigen toCD8aþ lymphoid tissue-
resident DCs. More recently, a subset of CD103þ DCs, which
share ontogenywith lymphoid tissue CD8aþ DCs, were shown
to take up antigen in the lung and skin and, after activation, to
cross-prime CD8þ T cells in the draining LNs.6,7
The identification of cells capable of cross-priming in the
intestinal mucosa remains controversial. Intestinal macro-
phages are able to capture and cross-present soluble antigen8
but are absent from intestinal lymph9,10 and are therefore
unlikely to initiate priming of naive T cells in mesenteric LNs
(MLNs). Intestinal CD103þ lamina propria (LP) DCs can be
separated into CD8aþ and CD8a subsets, both of which are
capable of initiating CTL differentiation after incubation with
soluble antigen in vitro.11 Although it was suggested that CD8þ
intestinal DCs derive exclusively from Peyer’s patches and are
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unlikely to migrate to MLNs,12 we have demonstrated that
CD8aþ DCs continuously migrate in intestinal lymph. In fact,
they are abundant even in the intestine and lymph of mice
lacking all intestinal lymphoid tissues, indicating that the
majority of CD8aþ intestinal DCs derive from the LP of the
conventional villus mucosa.10 In addition to the two subsets of
CD103þ DCs, a detailed survey of intestinal lymph DCs
(LDCs) revealed subsets of bona fide CD103 intestinal DCs.
Notably, all CD103þ and CD103 LDC subsets were able to
cross-present soluble antigen in vitro.10 It is not currently clear
which of these DC populations is responsible for cross-
presentation of intestinal antigen and priming of CTL
responses in vivo. Crucially, soluble antigens have been used
by the majority of studies to date; this does not represent the
physiological source of antigen involved in cross-priming
CTLs. Cross-priming of virus-specific CD8þ T cells requires
presentation of cell-associated antigens.6,13 Therefore, it is of
vital importance to unambiguously characterize the popula-
tions involved in the cross-presentation of cellular antigens and
the initiation of CTL responses.
Here we use transgenic mice that express intracellular
ovalbumin (OVA) only in mature intestinal epithelial cells
(IECs),14 to assess the capacity of intestinal DC subsets to
capture cellular antigens and prime CD8þ T cells. Interest-
ingly, we find that cross-presentation of IEC-expressedOVA in
the MLNs is entirely dependent on the CD103þ CD8aþ
migratory DC population, and absent from all other intestinal
and MLN DC subsets. Furthermore, we demonstrate that the
CD103þ CD8aþ subset of migrating intestinal DCs is both
necessary and sufficient to induce proliferation of gut-tropic
CD8þ T cells in vivo in response to IEC antigen. Finally, we
show that under inflammatory conditions the CD103þ
CD8aþ subset of intestinal lymph DCs induces cross-priming
of naive CD8þ T cells, driving their differentiation into
interferon g (IFN-g)-producing effector cells. These data
demonstrate, for the first time, the unique abilities of migratory
intestinal CD8aþ DCs to acquire and transport intracellular
IEC-derived antigen from the intestine and to directly drive the
initial differentiation of naive TCD8þ T cells into effector cells.
RESULTS
IEC-expressedOVA is efficiently presented to CD8þ T cells
Themajority of data on the cross-presenting ability of intestinal
DCs concerns their uptake and presentation of soluble antigen.
However, following infection with intracellular pathogens that
do not infect antigen-presenting cells directly, cross-presenta-
tion of cell-associated antigens is essential. Hence we used
IFABP-tOVA 232-4 (232-4) mice, which express OVA as an
intracellular antigen exclusively in mature IECs. When
transferred into steady-state 232-4 mice, transgenic OVA-
specific OT-I CD8þ T cells proliferate and migrate to the
intestinal LP, but do not mediate killing of OVA-expressing
IECs.14 However, in the presence of an inflammatory stimulus,
delivered by viral infection or addition of adjuvant, OT-I cells
transferred into 232-4mice differentiate intoCTLs andmediate
destruction of the intestinal epithelium.14,15 Similarly, we find
that this differentiation of OT-I cells into CTLs also occurs after
treatment of recipient 232-4 mice with R848, a Toll-like
receptor 7 (TLR7) agonist. 232-4 animals that receive OT-I cells
and R848 develop small intestinal inflammation characterized
by weight loss (Figure 1a), prodigious infiltration of CD8þ
T cells (Figure 1b), destruction of the epithelial-cell layer
(Figure 1c), shortening of the villi (Figure 1d), and high levels
of IFN-g in serum (Figure 1e). Therefore, 232-4 animals can be
used to investigate mechanisms involved in the cross-
presentation of IEC antigen, and the induction of effector
CD8þ T-cell responses in vivo.
Only CD103þ CD11b CD8aþ migrating DCs present IEC
antigen to CD8þ T cells
Since IEC-expressedOVA is efficiently cross-presented toOT-I
CD8þ T cells, we used the 232-4 mice to determine which DC
populations are able to capture, transport, and present this
antigen. In order to identify and purify all migratory DC
populations in lymph, unequivocally and without bias, we
purified by fluorescence-activated cell sorting the four distinct
LDC subsets that are obtained after thoracic duct cannulation
of mesenteric lymphadenectomized (MLNx) mice (Figure 2a).
This technique allows the collection of all DCs that would
normally migrate from the intestine to the MLNs, without
contamination by DCs from other tissues.10 All four subsets of
intestinal LDCs from wild-type mice cross-presented soluble
OVA to OT-I CD8þ T cells (Figure 2b). In contrast, when the
LDC subsets were purified from 232-4 mice and co-cultured
with OT-I cells without addition of soluble OVA, only the
CD103þ CD11b DCs could cross-present IEC-associated
antigen in vitro (Figure 2c).
Several reports suggest that the capacity to cross-present in
LNs is limited to a subset of CD8a-expressing DCs, which are
assumed to be blood derived and LN resident.12,16 However,
our results indicate that migrating lymph-borne CD103þ
CD11b DCs are able to directly present IEC-derived antigen
to T cells. In order to compare the relative contributions of
migratory and resident MLN DCs to cross-presentation, we
purified the migratory (CD11cþ MHCIIhi) and LN-resident
DCs (CD11chi MHCIIþ ) from the MLNs of 232-4 mice
(Figure 3a), using a strategy that has been previously
described.17 To ensure that plasmacytoid DCs did not conta-
minate these purified populations, B220þ cells were also
excluded from the cell sorts. As we have previously observed in
lymph, the migratory CD103þ CD11b DCs express CD8a,10
albeit at lower levels than the MLN-resident CD11b DCs
(Figure 3b). The purified migratory and resident MLN DCs
were then cultured with OT-I T cells. We found that the ability
to cross-present was entirely contained within the CD103þ
CD11b population of the migratory CD11cþ MHCIIhi MLN
DCs, and was absent from the ‘‘resident’’ CD8aþ CD11b
DCs (Figure 3c,d). CD11bþ subsets of both migratory and
resident DCs had no cross-presenting activity in these
experiments. Consistent with these results, we also observed
that when LPDCs from 232-4mice were co-cultured withOT-I
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cells, only the CD103þ CD11b DCs were able to cross-
present IEC-derived OVA to the OT-I cells (Supplementary
Figure S1 online).
In order to eliminate the possibility that 232-4 DCs can
express and present endogenous OVA, we used a bone marrow
chimera approach. In bone marrow chimeric mice where OVA
is only expressed in the non-hematopoietic compartment,
donor wild-type CD103þ CD11b MLN DCs efficiently
cross-presentedOVA toOT-I cells. However, when 232-4 bone
marrow was transplanted into wild-type recipients, donor
MLN DCs were not able to induce OT-I proliferation
(Supplementary Figure S2). Therefore, the induction of
OT-I proliferation was entirely due to cross-presentation of
IEC-derived OVA, and not due to OVA expression in the DCs
themselves. Finally, in order to test whether we can directly
observe IEC-associated antigen in any of the MLN DC subsets,
we adapted a technique for detecting vesicles containing
epithelial-cell cytokeratin in DCs.18 Discrete cytokeratinþ
inclusions were observed in flow-sorted DC cytospin prepara-
tions and were significantly more frequent in the migratory
CD103þ CD11b DCs compared to other MLN DC subsets
(Figure 3e,f).
These results demonstrate that only a single subset of
intestinal DCs—the migratory CD11cþ MHCIIhi CD103þ
CD11b CD8aþ DCs—is able to cross-present IEC-derived
antigen in the MLNs.
Intestinal CD103þ CD11b CD8aþ migrating DCs are
phenotypically and ontogenically similar to other cross-
presenting DC populations
Cross-presenting DC populations in the spleen, LNs, and lung
share several important characteristics, including the surface
expression of DNGR-119,20 and XCR121,22 and a requirement
for Batf3 and IRF8 in their development.16 In order to assess
whether the cross-presenting migratory intestinal CD103þ
CD11b DCs also display these properties, LDCs were
examined for the expression of a range of surface markers
by flow cytometry (Figure 4a). All subsets of LDCs lacked the
expression of the macrophage markers MerTK, CD64, and
CD14 but expressed theDC-specific markers CD26, CD24, and
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Figure 1 Stimulation with R848 after transfer of OT-I cells into IFABP-tOVA 232-4 (232-4) mice causes intestinal inflammation. 232-4 mice were
injected intravenously with 5 106 CD45.1þ OT-I cells, and a day later received R848 or phosphate-buffered saline intraperitoneally. (a) Themice were
weighed daily, shown here as percentage of startingweight. Each point represents themean of five biological replicates. (b)On day 5, cells from the small
intestinal lamina propria were stained for flow cytometry, and the number of CD45.1þ OT-I cells determined. (c) Sections of small intestine from mice
injected with OT-I cells, OT-I cells and R848, or with saline alone, were stained with hematoxylin and eosin to observe the pathology. (d) Themean villus
length in the jejunumwas calculated aftermeasuring at least 50 villi fromeachanimal. (e) Serumsampleswereobtained5daysafter R848administration,
and the levels of serum IFN-g were determined by ELISA. In all panels asterisks denote statistical significance (*Po0.05, **Po0.01). ELISA, enzyme-
linked immunosorbent assay; IFN-g, interferon g.
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CD272. Compared with other subsets of intestinal LDCs, the
CD103þ CD11b LDCs expressed the highest levels of CD272
and were unique in expressing high levels of CD8a, XCR1,
and DNGR-1 (Clec-9A) and lacking expression of CD172a
(Figure 4a). In order to examine whether migrating intestinal
CD103þ CD11b CD8aþ LDCs share ontogeny with
cross-presenting populations in other tissues, we made use
of Batf3 / mice that lack lymphoid tissue-resident CD8aþ
DCs and intestinal CD103þ CD11b DCs.16 As expected,
thoracic duct lymph from MLNx Batf3 / mice is signifi-
cantly depleted of the CD103þ CD11b CD8aþ LDCs
(Figure 4b). The CD103þ CD11b CD8aþ subset of LDCs
also expressed significantly higher levels of Irf8mRNA than the
other lymph DC populations (Figure 4c). These results
demonstrate that migrating intestinal CD103þ CD11b
CD8aþ LDCs share the ontogeny and many phenotypic
characteristics with cross-presenting DCs in other tissues.
Migratory intestinal CD103þ CD11b CD8aþ DCs are
sufficient and necessary for cross-presentation of IEC
antigen in the steady-state MLNs
Previous studies have shown that in the absence of an inflam-
matory stimulus, OT-I CD8þ T cells in 232-4 mice recognize
IEC-derived OVA, proliferate, and acquire the capacity to
migrate to the intestinal LP. However, they do not differentiate
into IFN-g-producing CTLs.14 To determine whether the
CD103þ CD11b CD8aþ 232-4 LDC subset alone was
sufficient to cross-present IEC-derived antigen and drive this
proliferation of naive CD8þ OT-I T cells in vivo, we used the
approach outlined in Figure 5a. Briefly, carboxyfluorescein
succinimidyl ester-labeled OVA-specific OT-I T cells were
transferred intravenously into congenic wild-type mice. A day
later, purified LDC populations from 232-4 mice were injected
directly into the subcapsular lymphatic sinus of the MLNs
(subcapsular injection). Three days later, LNs were collected
and the transferred OT-I cells examined to determine whether
any of the transferred DC subsets had induced their
proliferation. Since no exogenous OVA was added in this
system, any proliferation of OT-I T cells must result from the
cross-presentation of IEC-derived OVA by the LDCs
transferred into the MLNs from the 232-4 mice. OT-I cell
proliferation was detected in the MLNs of mice that had
received CD103þ CD11b CD8aþ LDC, whereas all the
other DC subsets were unable to stimulate OT-I prolife-
ration (Figure 5b). This T-cell priming was localized, as
no proliferation of transferred OT-I cells could be observed
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Figure 2 Intestinal epithelial-cell-expressed ovalbumin is cross-presented by migrating CD103þ CD11b lymph dendritic cells (LDCs). Thoracic duct
cannulationwasperformedon12-week-oldmesenteric lymphadenectomized (MLNx)C57Bl6 or IFABP-tOVA232-4 (232-4)miceand lymph collected for
16 h, on ice. Lymph cell populationswere purifiedwith fluorescence-activated cell sorting as shown in a. (b) 12,500C57Bl6 LDCs of the indicated subsets
were pulsed with ovalbumin, then extensively washed. DCswere then co-cultured with 105 carboxyfluorescein succinimidyl ester (CFSE)-labeledCD8þ
CD62Lþ OT-I cells for 3 days. Histograms represent proliferation as assessed by CFSE dilution. (c,d) 232-4 LDC subsets were plated out without the
addition of soluble ovalbumin. TheDCs’ capacity to driveCD8þ T-cell proliferationwas thenassessedasabove. (c)Histograms represent proliferation as
assessed by CFSE dilution. (d) The graph shows the mean percentage of divided T cells; each dot represents an independent experiment. Asterisks
denote statistical significance (**Po0.01). MHC II, major histocompatibility complex class II molecules.
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in the peripheral inguinal LNs of the same mice (data not
shown).
Next, we examined whether the T cells activated by the
CD103þ CD11b CD8aþ LDC in vivo acquired the
characteristic gut-homing phenotype induced by intestinal
andMLNDCs.10,23,24 Indeed, proliferating CD8þ T cells in the
MLNs showed increased expression of CCR9, an intestinal
homing chemokine receptor (Figure 5b). Furthermore,
CCR9þ CFSEdim transferred CD8þ OT-I T cells were
readily detectable in the small intestinal LP of mice that
had received CD103þ CD11b CD8aþ , but not in recipients
of other LDC subsets (Figure 5c). These data conclusively
demonstrate that the CD103þ CD11b CD8aþ subset of
migrating intestinal DCs is the only migratory DC population
capable of cross-presenting IEC-derived antigen to naı¨ve MLN
CD8þ T cells in vivo.
After activation with a TLR7 agonist, migratory intestinal
CD103þ CD11b CD8aþ DCs induce effector CD8þ T-cell
responses to IEC-derived antigen
We next examined whether the same subset of intestinal DCs
is also responsible for cross-priming CTL responses to
IEC-derived antigen under inflammatory conditions. Our data
clearly indicate that, in the steady state, migratory CD103þ
CD11b CD8aþ LDCs are the only cells able to cross-present
IEC-derived antigen to OT-I T cells. It is possible that other DC
populations may acquire cross-presenting and cross-priming
capacities following activation.25,26 Indeed it has been proposed
that LP-derived intestinal CD8a DCs are more efficient than
CD8aþ DCs at inducingCTL responses to soluble antigen after
TLR activation.11 To examine whether the ability to initiate
cross-priming of CD8þ T-cell responses to IEC-derived antigen
remained restricted to the CD103þ CD11b CD8aþ subset of
LDCs under inflammatory conditions, LDCs were isolated
from 232-4 mice after a single intraperitoneal dose of R848.
CD103þ CD11b CD8aþ 232-4 LDCs or LDCs depleted of
this subset were then purified and injected subcapsularly into
the MLNs of wild-type recipients of OT-I cells.
As in steady state, the subcapsular transfer of CD103þ
CD11b CD8aþ LDCs induced marked proliferation of
OT-I cells in the recipient MLNs, whereas LDCs that had been
depleted of the CD103þ CD11b CD8aþ subset were unable
to induce OT-I proliferation (Figure 6a). The CD103þ
CD11b CD8aþ LDCs from R848-treated 232-4 mice also
induced IFN-g production from the dividing OT-I T cells,
although no IFN-gwas detected after transfer of LDCs depleted
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Figure 3 Intestinal epithelial-cell-expressed ovalbumin is cross-presented by migrating CD103þ CD11b mesenteric lymph node dendritic cells
(MLN DCs). (a) Single-cell suspensions of IFABP-tOVA 232-4 mice MLNs were stained for flow cytometry and DC subsets were purified with
fluorescence-activated cell sorting as shown. (b) Levels of CD8a expression were assessed on MLN migratory CD103þ CD11b DCs (blue line) and
MLN-resident CD11b DCs (red line). The shaded histogram shows staining of the total MLN DC population with the isotype control antibody. (c,d)
12,500 MLN DCs of the indicated subsets were assessed for their capacity to drive OT-I T-cell proliferation. (c) Histograms represent proliferation as
assessed by carboxyfluorescein succinimidyl ester dilution. (d) The graph shows the mean percentage of divided T cells; each dot represents an
independent experiment. (e) Cytospins of MLN DC subsets purified as in a were stained with a pan-cytokeratin antibody (green) and DAPI (blue). The
images show examples of cytokeratinþ inclusions within the CD103þ CD11b migratory MLN DCs. The images show fluorescent signal overlaid on
white light images. Bar¼ 10mm. (f) The graph shows the mean percentage of cells of the indicated DC subsets containing visible cytokeratinþ
cytoplasmic inclusions. In all panels asterisks denote statistical significance (*Po0.05, **Po0.01). MHC II, major histocompatibility complex class II
molecules.
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of this subset (Figure 6b). Importantly, despite inducingCD8þ
T-cell proliferation in vivo, CD103þ CD11b CD8aþ DCs
from control 232-4 mice that did not receive R848 were also
unable to drive the production of IFN-g from transferred
OT-I T cells (Figure 6b). These results demonstrate that
activation of CD8aþ LDCs by a TLR agonist allows them to
prime effector CD8þ T cells. In contrast, despite stimulation
with a TLR agonist, the CD8a LDC subsets were unable to
cross-present IEC antigen or induce CD8þ T-cell effector
differentiation, indicating that they are not involved in cross-
presentation or induction of CTL responses. Finally, as in the
steady state, transferred OT-I T cells were only observed in the
intestinal LP of mice that had received subcapsular CD8aþ
LDCs (Figure 6c).
Taken together, our results demonstrate that, unlike soluble
antigen, intestinal cellular antigen is transported and cross-
presented to MLN CD8þ T cells in vivo by a single subset of
intestinal DCs, defined by their CD103þ CD11b CD8aþ
phenotype, both in the steady state and after TLR7-induced
activation.
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Figure 5 Only intestinal lymph CD103þ CD11b CD8aþ dendritic cells (DCs) cross-present intestinal epithelial cell antigen in vivo. (a) Schematic
shows the experimental protocol. Five days after subcapsular injections of 50,000 fluorescence-activated cell sorting (FACS) purified lymph DC (LDC)
subsets, mesenteric lymph nodes (MLNs) and the small intestine (SI) were harvested from recipient mice. Cells were then stained for flow cytometry.
Transferred OT-I T cells were identified as CD8þ CD45.1þ TCR Va2þ in the MLNs (b) or SI lamina propria (LP) (c), and assessed for proliferation by
carboxyfluorescein succinimidyl ester (CFSE) dilution. (b) For each injected LDC subset, FACS plots show the relative proportion of transferred OT-I T
cells (CD45.1þ CD8þ ) among TCRVa2þ cells (top left), CFSE dilution (top right), and CCR9 expression (bottom left) in the MLNs. The graph shows
meanpercentage of dividedT cells; each dot represents an independent experiment. Asterisks denote statistical significance (**Po0.01). (c) FACSplots
show the relative proportionof transferredOT-I T cells amongTCRVa2þ cells (left) orCFSEdilution andCCR9expressionof transferredOT-I cells (right)
in the LP, and are representative of two independent experiments. i.v., intravenous.
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DISCUSSION
Cross-presentation of cellular antigens by DCs is crucial for the
priming of CTLs capable of killing tumors or virally infected
cells. However, the identity of the DCs responsible for cross-
presentation in the intestinal mucosa is unclear; several
subtypes of intestinal DCs and macrophages are able to
cross-present soluble antigen.8,11,27 By isolating DCs directly
from lymph, we were able to analyze the function of all the DC
populations that migrate from the intestine to the MLNs. All
four subsets of migrating intestinal DCs can induce prolifera-
tion of antigen-specific OT-I CD8þ T cells in response to
soluble antigen. However, to understand how CD8þ T-cell
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Figure 6 Activated intestinal lymph CD8aþ dendritic cells (DCs) cross-prime effector CD8þ T cells. CD45.1þ C57Bl6 mice received 5 106
carboxyfluorescein succinimidyl ester (CFSE)-labeled CD45.2þ OT-I cells intravenously and, a day later, a subcapsular mesenteric lymph node (MLN)
injection of 50,000 CD103þ CD8aþ or CD8a lymph DCs (LDCs) isolated from R848-treated IFABP-tOVA 232-4 mice. Three days later, MLNs and
small intestine (SI) were removed and analyzed by flow cytometry. Transferred T cells were identified as CD8þ CD45.2þ TCR Va2þ . (a) Histograms
show the CFSE dilution of transferred OT-I cells in the MLNs following subcapsular transfer of the indicated LDC subsets. The graph shows the mean
percentage of divided cells. (b) Dot plots show representative staining for intracellular interferon g (IFN-g) on donor OT-I cells in the MLNs. The graph
shows the mean percentage of IFN-gþ cells among transferred OT-I cells. (c) FACS plots show the proportion of transferred OT-I T cells (CD45.2þ
CD8þ ) among TCRVa2þ cells in the SI lamina propria (LP). The graph shows the mean number of transferred cells in the SI LP. In all graphs, each dot
represents an independent biological replicate, and asterisks denote statistical significance (*Po0.05, **Po0.01).
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responses against viral and tumor antigens are initiated, it is
important to understand whichDCs present peripheral cellular
antigens to CD8þ T cells. We therefore assessed the cross-
presentation capacity of migratory DCs isolated from trans-
genic 232-4 mice, which express OVA exclusively in small
intestinal IECs.14 In this system, without the addition of any
soluble antigen, only the CD103þ CD11b CD8aþ LDCs, but
not the other LDC subsets, were able to induce proliferation and
differentiation of naı¨ve OVA-specific CD8þ T cells in vitro.
We show further that cross-presentation does not involve the
transfer of antigens to resident CD8aþ DCs in the draining
LNs, as has been suggested in other systems,5 as the only DCs
from 232-4 MLNs capable of priming CD8þ T cells were
CD103þ CD11b migratory DCs. All other MLN DC
populations, including the CD8ahi-resident DCs, were com-
pletely unable to cross-present IEC antigen. It is therefore
unlikely that antigen transfer from migratory to resident DCs
plays a major role in the cross-presentation of IEC-derived
cellular antigens during the induction phase of the response. As
has been indicated previously,10,28 we confirm that migrating
CD103þ CD11b also express CD8a, but at a lower level than
resident MLN DCs.
The CD103þ CD11b CD8aþ population of migrating
intestinal DCs shares the Batf3 and IRF-8-dependent ontogeny
with cross-presenting populations in both lymphoid and
peripheral organs,16 and expresses a very high level of surface
expression of XCR1, a chemokine receptor associated with
cross-presentation in mice and human DC subsets.21,22
Notably, the cross-presenting population of CD103þ CD8aþ
DCs were the only subset of DCs migrating in mouse lymph
that lacked the expression of CD172a (SIRPa). This is
consistent with previous evidence that an analogous population
of CD103þ CD172a LDCs in rat lymph can take up apoptotic
IECs and transport them toMLNs.18 In line with this, CD103þ
CD11b CD8aþ LDCs express DNGR-1 (Clec-9a), which is
involved in the uptake of dead cells and is expressed on cross-
presenting populations in mice and humans.19,20 Furthermore,
CD103þ CD11b DCs that migrate from the lung selectively
sample apoptotic cell antigen.6 Thus, it is highly likely that
intestinal CD103þ CD11b CD8aþ DCs and othermigratory
CD11b DCs utilize similar mechanisms to sample cellular
material, transport it to LNs, and present it to CD8þ T cells.
It has been suggested that CD103þ CD11b intestinal DCs
mainly derive from the lymphoid tissues of the intestine, such as
Peyer’s patches or isolated lymphoid follicles. However, we
have previously shown that these cells are present in normal
numbers in the intestine and lymph of mice lacking all
lymphoid tissues,10 suggesting that theymainly derive from the
LP. Further characterization of this LDC subset, including the
expression of DNGR-1 and XCR1, support this interpretation;
DCs expressing DNGR-1 (Clec-9a) can be found throughout
human non-lymphoid tissues, including the LP, where they can
be observed in the immediate vicinity of the intestinal
epithelium.20 Furthermore, XCR1-expressing cells can be
observed throughout the LP of the small intestinal villi
(Richard Kroczek, unpublished data) as well as in other
non-lymphoid tissues.21 Although we cannot rule out the
possibility that some CD103þ CD11b CD8aþ LDCs
originate in the lymphoid compartments of the intestine, it
is likely that they largely represent LP-derived migratory DCs.
Crucially, CD103þ CD11b CD8aþ DCs are also able to
cross-present IEC antigen to CD8þ T cells in vivo. By adapting
a technique described by the Pabst laboratory,29 we showed that
subcapsular injection of CD103þ CD11b CD8aþ LDCs, but
not other DC subsets, from the lymph of steady-state 232-4
mice into the MLNs led to clonal expansion of OT-I T cells.
The capacity of intestinal DCs to induce gut tropism in a
retinoic acid-dependent manner has been well character-
ized.24,30 However, it is not clear which intestinal DCs
are primarily responsible for inducing this phenotype in
CD8þ T cells. In contrast with an earlier report,11 we have
recently shown that CD103þ CD11b CD8aþ DCs have high
aldehyde dehydrogenase activity and can induce CCR9, a
marker of gut tropism on T cells, with a similar efficiency to the
other intestinal DC subsets.10 Here we show that, in vivo, cross-
presentation by CD103þ CD11b CD8aþ DCs also induces
CCR9 expression on responding OT-I T cells, and that, in this
experimental system, fully differentiated CCR9þ OT-I cells are
only detectable in the intestinal LP of mice after subcapsular
injection of CD103þ CD11b CD8aþ LDCs, but not other
LDC subsets.
Subcapsular transfer of steady-state CD103þ CD11b
CD8aþ LDCs causes T-cell proliferation, but does not induce
production of IFN-g. This replicates the phenotype of OT-I
cells transferred to 232-4 mice, which remain tolerant to OVA-
expressing IEC under steady-state conditions but, as we show
here, develop intoCTLswhen challengedwith theTLR7 agonist
R848. Importantly, CD103þ CD11b CD8aþ DCs isolated
from the lymphof 232-4mice treatedwithR848 are sufficient to
induce differentiation of CD8þ T cells into IFN-g-producing
gut-tropic T cells after subcapsular transfer into MLNs. In
addition, despite the suggestion that other DC populationsmay
acquire cross-presenting and cross-priming capacities follow-
ing activation,11,25,26 LDCs depleted of the CD8aþ subset
were unable to cross-present IEC antigen.
Taken together, these data definitively demonstrate that the
migrating CD103þ CD11b CD8aþ DCs play an essential
and exclusive role in the initial cross-presentation of cellular
antigens to naive CD8þ OT-I T cells in the MLNs and can, in
the presence of an inflammatory stimulus, initiate the
differentiation of IFN-gþ effector CD8þ T cells.
Our results suggest that plasticity of CD103þ CD11b
CD8aþ intestinal DCs is the crucial mechanism that controls
the balance between CD8þ T-cell-dependent homeostasis and
active immunity. Like other DCs, CD103þ CD11b CD8aþ
appear to be exquisitely sensitive to their environment.
They maintain tolerance under steady-state conditions,
but react to stimuli such as TLR ligands, and drive the
generation of effector CD8þ T cells. Selective targeting of these
processes inmigratoryCD103þ CD11b CD8aþ DCsmay be
a productive strategy for the generation of novel vaccines
against mucosal pathogens.
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METHODS
Animals. C57/Bl6 mice were purchased from Harlan and maintained
in individually ventilated cages. 232-4 IFABP-tOVA mice (a kind gift
from Professor Leo LeFrancois, University of Connecticut) and OT-I
mice were bred and maintained under specific pathogen-free con-
ditions at the Central Research Facility, Glasgow. All protocols
involving live animals were approved by the local ethical committee
and conducted under licenses issued by the UK Home Office.
Batf3 / mice were bred in specific pathogen-free conditions at the
Experimental Biomedicine Animal Facility, University of Gothenburg.
Surgical procedures. Mesenteric lymphadenectomy and thoracic
duct cannulation procedures were performed according to established
protocols.10 Mesenteric lymphadenectomy was performed on 6-week-
old C57/Bl6 or 232-4 male mice by laparotomy and blunt dissection.
Sixweeks later,micewere fed 0.2ml olive oil to visualize the lymphatics
and the thoracic lymph duct was cannulated by the insertion of a
polyurethane cannula (2Fr, Linton Instrumentation, Diss, UK).
Lymph was collected in phosphate-buffered saline with 20Uml 1 of
heparin sodium (Wockhardt UK, Wrexham, UK), on ice, for up to
16 h. Subcapsular MLN injections of cells were adapted from a
technique for intralymphatic injections.29 Briefly, cells were resus-
pended in o10 ml of saline and injected into the subcapsular lymph
sinus of the MLNs, using a BD Micro-Fine 30G needle (BD Bios-
ciences, Oxford, UK). During surgical procedures the animals were
maintained under inhalation anesthesia with isoflurane (Abbott
Animal Health, Abbott Park, IL).
Generation of bonemarrow chimeras. Eight-week-old mice received
a lethal dose of radiation (10Gy) and were reconstituted with 5 106
bone marrow cells by intravenous injection. Six weeks later, MLNs
were harvested for DC isolation.
Reagents. Cells were cultured in RPMI 1640, supplemented with
100Uml 1 penicillin, 100 mgml 1 streptomycin, 2mM L-glutamine,
5% fetal calf serum (all from Invitrogen, Paisley, UK), and 50 mM
2-mercaptoethanol (2-ME; Sigma-Aldrich, St Louis, MO). Intra-
peritoneal injections of 10 mg of R848 (Resiquimod; Invivogen,
San Diego, CA) were used to activate DCs in vivo.
Antibodies. Fluorochrome-conjugated monoclonal antibodies to
mouse antigens: TCRVa2 (B20.1), CD11b (M1/70), CD11c (N418),
CD24 (30-F1), CD26 (H194-112), CD45 (30-F11), CD45.1 (A20),
CD45.2 (104), B220 (RA3–6B2), CD62L (MEL-14), CD64 (X54-5/7.1),
CD103 (2E7), CLEC9A (7H11), and CCR9 (CW-1.2) were purchased
from BioLegend (San Diego, CA). Monoclonal antibodies to mouse
CD8a (53–6.7), CD172a (P84), and IFN-g (XMG1.2) were from BD
Biosciences (Oxford, UK). The I-A/I-E MHCII (M5/114.15.2), CD14
(Sa2–8), and CD272 (6F7) antibodies were purchased from
eBioscience (San Diego, CA). Biotinylated antibody to mouse MerTK
(BAF591) was purchased from R&D Systems (Minneapolis, MN).
XCR1 mAb (MARX-10) was generated as described.22 The 7AAD
dead cell exclusion dye, streptavidin reagents, and mouse isotype
control antibodies, conjugated to appropriate fluorochromes, were
purchased from BioLegend.
Cell isolation. Thoracic duct leukocytes were collected on ice in
phosphate-buffered saline with 20Uml 1 heparin, passed through a
40-mm cell strainer (BD Biosciences), and RBCs lysed with ACK
(ammonium–chloride–potassium) lysis buffer (Sigma-Aldrich). Cells
were stained and analyzed by flow cytometry or sorted by fluorescence-
activated cell sorting using the FACSAria cell sorter (BD Biosciences).
Small intestines were flushed with Hank’s balanced salt solution
with 2% fetal calf serum and the Peyer’s patches excised. The intestines
were opened longitudinally and cut into 0.5-cm segments, which were
incubated twice in Hank’s balanced salt solution with 2-mM
ethylenediaminetetraacetic acid at 37 1C while shaking for 20min.
Supernatants were discarded and the tissue digestedwith 1mgml 1 of
collagenase VIII (Sigma-Aldrich) at 37 1C with shaking for 15min.
MLNs were macerated and incubated with 0.4 Wunsch units per
milliliter of Blendzyme and 50 mgml 1 of DNAse (both from Roche,
Penzberg, Germany) for 45min at 37 1C while shaking. Single-cell
suspensions were passed through a 40-mm cell strainer and stained for
flow cytometry.
Flow cytometry. Cell surface staining was performed in phosphate-
buffered saline with 2% fetal calf serum and 10mM ethylenediami-
netetraacetic acid for 30min on ice.Where biotin-conjugated antibody
was used, cells were further stained with a streptavidin-fluorochrome
conjugate for 15min. Samples were acquired on LSRII (BD Bio-
sciences) or MACSQuant (Miltenyi Biotec) flow cytometers, or sorted
and analyzed by the FACSAria cell sorter (BD Biosciences). For
intracellular cytokine staining, cells were incubated for 4 h with
phorbol 12-myristate 13-acetate, ionomycin, brefeldin A, and
monensin (all from eBioscience). Cells were stained for surfacemarker
expression andwashed. Cells were then fixed in 4%paraformaldehyde,
permeabilized, and stained for intracellular cytokine. Acquired
data were analyzed using FlowJo software (version 9.3.1; Tree Star,
Ashland, OR).
Microscopy. Dissected tissues were immediately fixed in neutral
buffered formalin. They were embedded in paraffin, sectioned (5 mm),
and stained with hematoxylin and eosin. Images were obtained using a
light microscope at  10 magnification and were analyzed, and
archived using cell^B software (Olympus, Tokyo, Japan).
For cytospins, cells were centrifuged (300 r.p.m., 5min) onto poly-L-
lysine coated slides (VWR International, Radnor, PA), fixed in
acetone, and stained with the anti-mouse pan-cytokeratin (C-11;
Sigma-Aldrich) or isotype control antibody. Images were obtained
using the EVOS Cell Imaging System (Life Technologies).
Proliferation assay. Sorted C57/Bl6 LDCs were pulsed with
2mgml 1 of OVA (Worthington, Lakewood, NJ) for 2 h at 37 1C
and then extensively washed. They or unpulsed 232-4 LDCs were
cultured at varying ratios with 105 carboxyfluorescein succinimidyl
ester-labeled naive OT-I CD8þ T cells at 37 1C for 3 days.
Carboxyfluorescein succinimidyl ester dilution was assessed by flow
cytometry.
Serum cytokine detection. Serum concentration of IFN-g was
assessed by ELISA (enzyme-linked immunosorbent assay; Millipore,
Billerica,MA) according to themanufacturer’s instructions.Minimum
detectable concentration was o5 pgml 1.
RNAextraction. RNAwas extracted using theMicroRNA kit (Qiagen,
Venlo, Netherlands) according to the manufacturer’s instructions.
Contaminating genomic DNA was removed using the DNA-free kit
(Qiagen). RNA was reverse transcribed using the Superscript First
Strand kit (Invitrogen).
Real-timequantitativePCR. cDNAwas examined for the frequency of
the Irf8 transcript by quantitative real-time PCR using the Brilliant III
Ultra Fast SYBR qPCRmaster mix (Agilent Technologies, Santa Clara,
CA). Fluorescence levels were detected and analyzed using the 7900HT
Fast system (Applied Biosystems). Relative quantification was
determined using the DDCt method and normalized to expression of
the housekeeping gene cyclophilin A.
Primers used were cyclophilin A: forward 50-GTGGTCTTTG
GGAAGGTGAA-30, reverse 50-TTACAGGACATTGCGAGCAG-30;
IRF8: forward 50-GAGCGAAGTTCCTGAGATGG, reverse 50-TGGG
CTCCTCTTGGTCATAC-30.
Statistical analysis. For comparison of means between two groups,
the data were analyzed by Student’s t-test. For comparisons involving
more than two data sets, analysis of variance was used. P valueso0.05
were considered significant and Bonferroni post-test was performed
on the data sets. Unless otherwise stated, asterisks denote significant
difference of the indicated group from all other groups. All statistical
analysis was performed using GraphPad Prism and Microsoft Excel.
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